Moderna’s investigational mRNA-1010 vaccine generates a broader and more durable immune response than standard flu shots, according to a study published in Nature Immunology. Researchers at Washington University School of Medicine in St. Louis found the vaccine helps the immune system recognize a wider array of influenza strains. This mechanism may offer superior protection when circulating flu viruses do not perfectly match the vaccine.
Study participants receiving the mRNA vaccine produced higher levels of flu-specific antibodies and memory B cells compared to those given standard shots.
The U.S. Food and Drug Administration (FDA) is currently reviewing mRNA-1010 for potential approval. If authorized, it would become the first mRNA-based influenza vaccine available on the market.